Model modification/subgroup | Concordance index | 95% confidence interval |
---|---|---|
Training cohort | ||
 The US, our nomogram | 0.60 | 0.59–0.61 |
 The US, model based on both T and N stages | 0.56 | 0.56–0.57 |
Validation cohorts | ||
 Belgium, our nomogram | 0.58 | 0.55–0.60 |
 Belgium, model based on both T and N stages | 0.54 | 0.52–0.56 |
 The Netherlands, our nomogram | 0.62 | 0.59–0.65 |
 The Netherlands, model based on both T and N stages | 0.56 | 0.54–0.59 |
 Slovenia, our nomogram | 0.58 | 0.51–0.65 |
 Slovenia, model based on both T and N stages | 0.52 | 0.47–0.57 |
 Norway, our nomogram | 0.63 | 0.55–0.71 |
 Norway, model based on both T and N stages | 0.61 | 0.54–0.68 |
Sensitivity analyses for the training US cohort | ||
 Replacement | ||
  Age group in place of continuous age | 0.59 | 0.59–0.60 |
  Metastatic lymph node number in place of N stage | 0.60 | 0.59–0.61 |
  Lymph node ratio in place of N stage | 0.61 | 0.61–0.62 |
  The 8th version of T stage in place of the original stage | 0.61 | 0.60–0.61 |
  The 8th version of N stage in place of the original stage | 0.60 | 0.59–0.61 |
  The 8th version of T & N stages in place of the original stages | 0.61 | 0.60–0.62 |
 Addition | ||
  Harvested lymph node added | 0.60 | 0.60–0.61 |
  Tumor size added | 0.61 | 0.60–0.61 |
  Harvested lymph node & tumor size added | 0.61 | 0.60–0.62 |
 Subgroup | ||
  Diagnosis after 2009 | 0.60 | 0.59–0.61 |
  White ethnicity | 0.60 | 0.59–0.61 |
  Pancreas head | 0.60 | 0.59–0.61 |
  Pancreas body & tail | 0.61 | 0.59–0.63 |